Exclusion criteria: Clinical trials
YL: Writing original draft
The shot takes a couple of minutes, and you can return to your day right away
Researchers use this peptide to explore receptor activation, second-messenger cascades (e.g., cAMP production), and downstream effects on cellular metabolism in controlled laboratory and preclinical environments
This is where probiotics come in
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) demonstrate glucose-lowering, weight-reducing, and favourable anti-inflammatory and metabolic effects.1 These emerging drug classes have been proven to reduce cardiovascular events in patients with type 2 diabetes mellitus (T2DM) who are at high cardiovascular risk or have established cardiovascular disease.2 In this context, current guidelines recommend GLP-1RAs as first-line antidiabetic therapies in patients with established cardiovascular disease or high/very high cardiovascular risk.3 Semaglutide is a potent GLP-1RA used in the treatment of T2DM, with demonstrated cardiovascular benefits